Truth Seeker
New Member
The objective was to determine whether a cannabis-based medicinal extract (CBME)
benefits a range of symptoms due to multiple sclerosis (MS). A parallel group,
double-blind, randomized, placebo-controlled study was undertaken in three
centres, recruiting 160 outpatients with MS experiencing significant problems
from at least one of the following: spasticity, spasms, bladder problems, tremor
or pain. The interventions were oromucosal sprays of matched placebo, or whole
plant CBME containing equal amounts of delta-9-tetrahydrocannabinol (THC) and
cannabidiol (CBD) at a dose of 2.5-120 mg of each daily, in divided doses. The
primary outcome measure was a Visual Analogue Scale (VAS) score for each
patient's most troublesome symptom. Additional measures included VAS scores of
other symptoms, and measures of disability, cognition, mood, sleep and fatigue.
Following CBME the primary symptom score reduced from mean (SE) 74.36 (11.1) to
48.89 (22.0) following CBME and from 74.31 (12.5) to 54.79 (26.3) following
placebo [ns]. Spasticity VAS scores were significantly reduced by CBME (Sativex)
in comparison with placebo (P =0.001). There were no significant adverse effects
on cognition or mood and intoxication was generally mild.
Source: Clinical Studies and Case Reports
benefits a range of symptoms due to multiple sclerosis (MS). A parallel group,
double-blind, randomized, placebo-controlled study was undertaken in three
centres, recruiting 160 outpatients with MS experiencing significant problems
from at least one of the following: spasticity, spasms, bladder problems, tremor
or pain. The interventions were oromucosal sprays of matched placebo, or whole
plant CBME containing equal amounts of delta-9-tetrahydrocannabinol (THC) and
cannabidiol (CBD) at a dose of 2.5-120 mg of each daily, in divided doses. The
primary outcome measure was a Visual Analogue Scale (VAS) score for each
patient's most troublesome symptom. Additional measures included VAS scores of
other symptoms, and measures of disability, cognition, mood, sleep and fatigue.
Following CBME the primary symptom score reduced from mean (SE) 74.36 (11.1) to
48.89 (22.0) following CBME and from 74.31 (12.5) to 54.79 (26.3) following
placebo [ns]. Spasticity VAS scores were significantly reduced by CBME (Sativex)
in comparison with placebo (P =0.001). There were no significant adverse effects
on cognition or mood and intoxication was generally mild.
Source: Clinical Studies and Case Reports
